Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02366728 · ClinicalTrials.gov registry record · Phase 2
DC Migration Study for Newly-Diagnosed GBM
A Phase 2 study, sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02366728 is a Phase 2 study that has completed, run by Mustafa Khasraw, MBChB, MD, FRCP, FRACP. The registered enrollment target is 64 participants.
The verdict
NCT02366728, a Phase 2 study, has completed, sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This randomized phase II study will assess the impact of pre-conditioning on migration and survival among newly diagnosed glioblastoma (GBM) patients who have undergone definitive resection and completed standard temozolomide (TMZ) and radiation treatment, as well as the impact of tetanus pre-conditioning and basiliximab together on survival. After completing standard of care radiotherapy with concurrent TMZ, patients will be randomized to 1 of 3 treatment arms: 1). receive cytomegalovirus (CMV)-specific dendritic cell (DC) vaccines with unpulsed (not loaded) DC pre-conditioning prior to the 4th vaccine; 2). receive CMV-specific DC vaccines with Tetanus-Diphtheria Toxoid (Td) pre-conditioning prior to the 4th vaccine; 3). receive basiliximab infusions prior to the 1st and 2nd DC vaccines along with Td pre-conditioning prior to the 4th vaccine. A permuted block randomization algorithm using a 1:1:1 allocation ratio will be used to assign patients to a treatment arm. Randomization will be stratified by CMV status (positive, negative), with the assignment to arms I and II being double-blinded. Effective March 2017, randomization to Group III has been terminated.
Interventions
- DRUG Temozolomide
- BIOLOGICAL Human CMV pp65-LAMP mRNA-pulsed autologous DCs
- BIOLOGICAL Td
- BIOLOGICAL Unpulsed DCs
- BIOLOGICAL 111In-labeled DCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-10-12 |
| Est. Completion | 2020-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02366728
The ClinicalTrials.gov registry entry for NCT02366728 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mustafa Khasraw, MBChB, MD, FRCP, FRACP, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Temozolomide is the first listed.
NCT02366728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02366728 about?
NCT02366728 is a clinical study titled "DC Migration Study for Newly-Diagnosed GBM". This randomized phase II study will assess the impact of pre-conditioning on migration and survival among newly diagnosed glioblastoma (GBM) patients who have undergone definitive resection and completed standard temozolomide (TMZ) and radiation treatment, as well as the impact of tetanus pre-condit...
What is the current status of trial NCT02366728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2015-10-12. Estimated completion is 2020-10-31.
What interventions are being tested in trial NCT02366728?
The interventions under investigation include: Temozolomide (DRUG), Human CMV pp65-LAMP mRNA-pulsed autologous DCs (BIOLOGICAL), Td (BIOLOGICAL), Unpulsed DCs (BIOLOGICAL), 111In-labeled DCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT02366728?
This trial is sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.